Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 2/20 | 0.73 |
| ▸ | GUSB | P08236 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | EGFR | P00533 | 10/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 10/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9701200 | 0.85 | GLA (0.67) | GLAGUSBALDH1A1LMNATHRB | |
| SCHEMBL16151836 | 0.85 | GLA (0.78) | GLAGUSBALDH1A1LMNATHRB | |
| SCHEMBL677158 | 0.85 | GLA (0.78) | GLAGUSBALDH1A1LMNATHRB | |
| SCHEMBL9702344 | 0.85 | GLA (0.73) | GLAGUSBALDH1A1LMNATHRB | |
| SCHEMBL9701605 | 0.84 | GLA (0.76) | GLAGUSBALDH1A1LMNATHRB | |
| SCHEMBL5143254 | 0.84 | GLA (0.76) | GLAGUSBALDH1A1LMNATHRB | |
| Bamnidazole SCHEMBL635607 | 0.84 | GLA (1.00) | GLAGUSBALDH1A1LMNATHRB | |
| SCHEMBL9701202 | 0.84 | GLA (0.71) | GLAGUSBALDH1A1LMNATHRB | |
| SCHEMBL9701341 | 0.84 | GLA (0.71) | GLAGUSBALDH1A1LMNATHRB | |
| SCHEMBL3772284 | 0.82 | GLA (0.73) | GLAGUSBALDH1A1LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317707-A1 | Oligomer-Nitroimidazole Anti-Infective Conjugates | NEKTAR THERAPEUTICS (US) | 2010-12-16 | — | — | US | claimed |
| US-9233932-B2 | Oligomer-nitroimidazole anti-infective conjugates | NEKTAR THERAPEUTICS (US) | 2016-01-12 | — | — | US | disclosed |
| US-20140378520-A1 | OLIGOMER-NITROIMIDAZOLE ANTI-INFECTIVE CONJUGATES | NEKTAR THERAPEUTICS | 2014-12-25 | — | — | US | disclosed |
| US-8853247-B2 | Oligomer-nitroimidazole anti-infective conjugates | NEKTAR THERAPEUTICS (US) | 2014-10-07 | — | — | US | disclosed |
| US-20100317707-A1 | Oligomer-Nitroimidazole Anti-Infective Conjugates | NEKTAR THERAPEUTICS (US) | 2010-12-16 | — | — | US | disclosed |
| WO-2009058387-A2 | OLIGOMER-NITROIMIDAZOLE ANTI-INFECTIVE CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378520-A1 | OLIGOMER-NITROIMIDAZOLE ANTI-INFECTIVE CONJUGATES | NOD2, NOD1, NEDD8 | GLA 4241/4885GUSB 2774/4885ALDH1A1 3342/4885 |
| US-20100317707-A1 | Oligomer-Nitroimidazole Anti-Infective Conjugates | NOD2, NOD1, NEDD8 | GLA 4268/4885GUSB 2811/4885ALDH1A1 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.